title: How to Think About Risk in Myeloma.
abstract: An integral part of myeloma therapy is risk stratification of newly diagnosed patients. This method involves a combination of staging and genetic risk assessment. Although survival has dramatically improved for patients with genetically defined, standard-risk myeloma, those with high-risk disease remain a therapeutic challenge. Current treatment approaches might include the use of combination therapy for induction and maintenance. Future approaches are expected to involve drugs that are "risk agnostic," such as monoclonal antibodies and immunotherapy.
authors: Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma, City of Hope, Duarte, CA. Electronic address: AKrishnan@coh.org.
authors: Amrita
authors: A
authors: Krishnan
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D003131:Combined Modality Therapy; D019468:Disease Management; D020022:Genetic Predisposition to Disease; D006403:Hematologic Tests; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D058990:Molecular Targeted Therapy; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D009367:Neoplasm Staging; D018570:Risk Assessment; D016896:Treatment Outcome
keywords: Bortezomib; Carfilzomib; Cytogenetics; Dexamethasone; Immunotherapy; Lenalidomide; Next-generation sequencing